| abstract |
the present invention relates to a method of treating a tumor in a human patient which comprises (i) identifying a patient as having a lag-3 positive tumor and (ii) administering to the patient an inhibitor of the pd-1 pathway , a combination of an inhibitor of the pd1 pathway and an inhibitor of the immune checkpoint, a combination of an inhibitor of the lag-3 and an inhibitor of the pd-1 pathway or an anti-ctla4 antibody. in some modalities, the method also involves identifying the patient as having a lag-3 positive and a pd-l1 positive tumor. in some embodiments, the lag-3 inhibitor is an anti-lag-3 antibody and the inhibitor of the pd-1 pathway is an anti-pd-1 antibody. the methods of the invention can improve response rates to treatment with a pd-1 pathway inhibitor, a combination of a pd1 pathway inhibitor and an immune checkpoint inhibitor or a combination of a lag-3 inhibitor and an inhibitor of the pd-1 pathway. |